Negev Capital

I'm incredibly grateful to share that the SoundSelf equity crowdfunding campaign is live – with over $100k already committed in the first few hours! If you've followed my work, you know that I’ve dedicated my career to pioneering tools that foster psychological and spiritual healing. After 12 years of work, SoundSelf is a breakthrough – a blend of ancient practices and cutting-edge tech that effectively evokes the visionary clarity and lasting wellbeing enhancements that are associated with psychedelics... without any drug. This is especially important with the FDA's recent rejection of MDMA. SoundSelf can provide the healing power of altered states *now*. Today, we’re on a mission to reach $150k by day’s end, bringing this transformative tool to more people in need. Your support could make a lasting impact on the future of mental health—join us now and be part of something truly extraordinary.

SoundSelf Wefunder Raise if Off to a Great Start We've hit our first milestone: $107,500 reserved by 11 investors! Why Invest in SoundSelf? Our immersive, drug-free digital therapeutic is revolutionizing mental health care, proven to reduce depression and anxiety while boosting wellness. With 450 clinicians on our waitlist and strong support from investors like Mystic Ventures, we're ready to scale. Clinician Approved, Patient Loved "SoundSelf takes ketamine therapy to the next level," says Jessica S., Psychiatric Nurse Practitioner. Join Us: www.wefunder.com/soundself We are 'testing the waters' to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. If sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and only through Wefunder’s platform. Any indication of interest involves no obligation or commitment of any kind.

🎤 𝗘𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲 𝗦𝗼𝘂𝗻𝗱𝗦𝗲𝗹𝗳: 𝗜𝗺𝗺𝗲𝗿𝘀𝗶𝘃𝗲 𝗗𝗲𝗺𝗼 𝗗𝗮𝘆 𝗶𝗻 𝗦𝗮𝗻 𝗙𝗿𝗮𝗻𝗰𝗶𝘀𝗰𝗼 🎤 Journalists and investors are invited to an exclusive immersive demo of SoundSelf, the cutting-edge digital therapeutic that’s transforming mental health and psychedelic therapy. You’ll have the opportunity to personally experience this breakthrough technology that facilitates non-ordinary states of consciousness through sound, visuals, and biofeedback—all without medication. ˜”*°•.˜”*°• What to Expect: •°*”˜.•°*”˜ Over the course of a 60-minute demo, you will be guided through a deeply relaxing, sensory-rich journey that engages your voice, breath, and mind. This immersive experience mimics states achieved through meditation or psychedelic therapy, providing a glimpse of the therapeutic power SoundSelf offers to users. 𝐖𝐡𝐲 𝐀𝐭𝐭𝐞𝐧𝐝? Discover why clinics and wellness centers around the world are incorporating SoundSelf to enhance their mental health offerings and improve patient outcomes, especially for ketamine therapy preparation and integration. Learn firsthand how this innovative tool is reshaping the future of digital therapeutics. 📲 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗬𝗼𝘂𝗿 𝗜𝗻𝘁𝗲𝗿𝗲𝘀𝘁 Secure your spot now! Space is limited, so register early. Upon registration, you’ll receive a link to schedule a session that fits your day. 🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 https://lu.ma/0fxw177s ⚠️ Note: Due to light therapy usage, this experience is not suitable for individuals with epilepsy or seizure risks. Don’t miss this chance to experience the future of mental health and psychedelic therapy!

The impact of under-representation of women in clinical trials is significant and has resulted in an over-representation of serious adverse events and side effects from prescribed medications in women. Tune into Dr Rachael Sumner, who discusses the issues and the team's approach in newly approved clinical trials for negative mood symptom alleviation in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

Very excited to share the next stage of developing this promising depression treatment. 🔥 First dosing has started in a Phase 2B take-home microdosing (MB22001) clinical trial in patients with Major Depressive Disorder. In a series of world first trials, patients are sent home under regulatory approvals with MB22001, a proprietary, titratable form of LSD designed for safe take-home microdosing. 👨🏫 MB22001, in a large Phase 1 randomized controlled clinical trial is already shown to improve feelings of wellbeing, happiness, energy, creativity and social connectivity in healthy individuals. Trial participants also slept better, including longer REM sleep and felt less irritable and angry. 🔥🔥 This Phase 2B trial follows a recent successful Phase 2A trial which resulted in 53% of depressed patients being in complete remission from their depression after 8 weeks. Overall, the trial resulted in a 60% drop in depressive symptoms, a 14.1 drop in MADRS score, (Montgomery-Asberg Depression Rating Scale). 🙏 We must innovate to create better treatments for mental health conditions. This is looking very promising as a potential scalable solution to using psychedelic medicines (without the hallucinations) in patients at home.